188030-43-5

Basic information

• Product Name: N-(TERT-BUTOXYCARBONYL)-3,3,3-TRIFLUOROALANINE
• Synonyms: N-(TERT-BUTOXYCARBONYL)-3,3,3-TRIFLUOROALANINE;Alanine, N-[(1,1-dimethylethoxy)carbonyl]-3,3,3-trifluoro-
• CAS NO: 188030-43-5
• Molecular Formula: C₈H₁₂F₃NO₄
• Molecular Weight: 243.18
• Mol File: 188030-43-5.mol

Chemical Properties

• Boiling Point: 303.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.319±0.06 g/cm3(Predicted)
• PKA: 2.37±0.10(Predicted)
• CAS DataBase Reference: N-(TERT-BUTOXYCARBONYL)-3,3,3-TRIFLUOROALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(TERT-BUTOXYCARBONYL)-3,3,3-TRIFLUOROALANINE(188030-43-5)
• EPA Substance Registry System: N-(TERT-BUTOXYCARBONYL)-3,3,3-TRIFLUOROALANINE(188030-43-5)

Safety Data

• Hazardous Substances Data: 188030-43-5(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
N-(TERT-BUTOXYCARBONYL)-3,3,3-TRIFLUOROALANINE is used as a building block in the synthesis of peptides and other pharmaceutical agents for its unique properties that make it valuable in the development of novel drug candidates.
Used in Drug Development:
N-(TERT-BUTOXYCARBONYL)-3,3,3-TRIFLUOROALANINE is used as a key component in the creation of new pharmaceuticals, leveraging its highly fluorinated nature to enhance the properties of drug molecules.
Safety Considerations:
It is important to handle N-(TERT-BUTOXYCARBONYL)-3,3,3-TRIFLUOROALANINE with care, following proper safety protocols and procedures, due to its potentially hazardous nature.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 17463-43-3 3,3,3-trifluoro-DL-alanine 

Downstream Products

• 126536-02-5 (2,2,2-trifluoro-1-hydroxymethylethyl)carbamic acid tert-butyl ester 
• 1403943-20-3 tert-butyl 1,1,1-trifluoro-3-oxo-3-(2-(phenylcarbamoyl)-1H-pyrrol-1-ylamino)propan-2-ylcarbamate 
• 672959-90-9 tert-butyl [1-(2-methylphenylcarbamoyl)-1-trifluoromethyl-methyl]-carbamate 

Relevant articles and documents

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS

The present invention relates to compounds of Formula (I) and salts solvates and hydrates thereof. The invention further relates to pharmaceutical compositions containing said compounds and methods of treating neurological and neuropsychistric disorders using said compounds.